Skip to main content


Log in

Absorption, distribution, metabolism and excretion of the cholecystokinin-1 antagonist dexloxiglumide in the dog

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript


Single oral doses of14C-dexloxiglumide were rapidly and extensively absorbed in dogs and also eliminated rapidly with a short half-life. Following single intravenous doses, dexloxiglumide was characterised as a drug having a high clearance (30.7 and 27.0 ml/min/kg in males and females respectively), a low volume of distribution (Vss, 0.34 and 0.27 L/kg in males and females respectively) and a moderate systemic availability (about 33%). It was extensively bound to plasma proteins (89%). Dexloxiglumide is mainly cleared by the liver. Its renal clearance was minor. In only the kidney, liver and gastrointestinal tract, were concentrations of14C generally greater than those in plasma.14C concentrations generally peaked at 0.25h and declined rapidly during 24h being present only in a few tissues (such as the kidney, liver and gastrointestinal tract) at 24h.

Single intravenous or oral doses were mainly excreted in the faeces (77–89%), mostly during 24h. Urine contained up to 7.5% dose. Mean recoveries during 7 days ranged between 93–97%. Biliary excretion of14C was prominent (64% dose during 24h) in the disposition of14C which was probably also subjected to some limited enterohepatic circulation. Unchanged dexloxiglumide was the major component in plasma. Urine and faeces contained several14C-components amongst which unchanged dexloxiglumide was the most important (eg. about 55% dose in faeces). LC-MS/MS of urine and bile extracts showed that dexloxiglumide was metabolised mainly by O-demethylation and by conjugation with glucuronic acid.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others


  1. Woodruff G.N. and Hughes, J. (1991): Cholecystokinin antagonists. Ann. Rev. Pharmacol. Toxicol., 31, 469–501.

    Article  CAS  Google Scholar 

  2. D’Amato M., Makovec F., Rovati L.C. (1999b): CCKA-receptors in gastrointestinal disorders. Drug Development: Molecular Targets for GI Diseases, edited by T.S. Gaginella and A. Guglietta, (Totowa, NJ: Human Press) pp. 147–175.

    Google Scholar 

  3. Grider J.R. (1994): Role of cholecystokinin in the regulation of gastrointestinal motility. J. Nutrit., 124 (Suppl. 8), 1334S-1339S.

    CAS  PubMed  Google Scholar 

  4. Revel L., Makovec F., Castaner J. (1999): Dexloxiglumide — CCK 1 (CCKA) receptor antagonist treatment of irritable bowel syndrome. Drugs of the Future, 24, 725–728.

    Article  CAS  Google Scholar 

  5. Scarpignato C., Kisfalvi I., D’Amato M., and Varga G. (1996): Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Alimen. Pharmacol. Ther., 10, 411–419.

    Article  CAS  Google Scholar 

  6. Fioramonti J., D’Amato M., Rovati L., Buéno L. (1996) Effects of dexloxiglumide on gastric emptying delayed by colonic distension in dogs. Neurogastroenterol. Motil., 8, 172.

    Google Scholar 

  7. Rouzade M.L., Fioramonti J., D’Amato M., Rovati L., Buéno, L. (1996): Inhibitory action of dexloxiglumide on transient lower oesophageal sphincter relaxation in dogs. Neurogastroenterol. Motil., 8, 188.

    Google Scholar 

  8. Meier R., Beglinger C., Giacovelli G., D’Amato M. (1997): Effect of the CCK-A receptor antagonist dexloxiglumide on postprandial gallbladder emptying and colonic transit time in healthy volunteers, Gastroenterol., 112, A788.

    Google Scholar 

  9. D’Amato M., Whorwell P.J., Thompson D.G., Spiller R.C., Giacovelli G., Rovati L.C., (1999a): The efficacy and safety of the CCKA-receptor antagonist dexloxiglumide in IBS. Gut, 45 (Suppl. V), A258.

    Google Scholar 

  10. D’Amato M., Whorwell P.J., Thompson D.G., Spiller R.C., Giacovelli G., Griffin P.H., Schneier H. and Rovati L.C. (2001): CCK1-receptor antagonist dexloxiglumide is effective and safe in female patients with constipation predominant irritable bowel syndrome. Amer. J. Gastroenterol., 96, S317.

    Article  Google Scholar 

  11. Feinle C., Meier O., D’Amato M. (1999): CCK-A Receptor blockade improves dyspeptic symptoms due to duodenal lipid and gastric distension in functional dyspepsia. Gastroenterol., 116, (Suppl.), A992.

    Google Scholar 

  12. Webber C., Roth A., Persiani S., Peard A.J., Makovec A., Kapil R.P., John B.A., Holding J.D., D’Amato M., Cybulski Z.R., Chasseaud L.F. and Rovati L.C. (2003): Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects. Xenobiotica, 33, 625–641.

    Article  CAS  PubMed  Google Scholar 

  13. Webber C, Stokes, C.A., Persiani S., Makovec A., McBurney, A., John B.A., Houchen, T.L., D’Amato M. and Chasseaud L.F. (2003): Absorption, distribution, metabolism and excretion of the cholecystokinin-1 antagonist dexloxiglumide in the rat. Eur. J. Drug Metab. Pharmacokinet., 28m 210–212.

    Google Scholar 

  14. Davies B. and Morris T. (1993): Physiological parameters in laboratory animals and humans. Pharm. Res., 10, 1093–1095.

    Article  CAS  PubMed  Google Scholar 

  15. Hucker H.B., Kwan K.C., Duggan D.E. (1980): Pharmacokinetics and metabolism of non-steroidal anti-inflammatory agents. In Progress in Drug Metabolism, edited by J.W. Bridges and L.F. Chasseaud. (Chichester: Wiley), vol. 5, 165–253.

    Google Scholar 

  16. Hirom P.C., Idle J.R. and Millburn P. (1977): Comparative aspects of the biosynthesis and excretion of xenobiotic conjugates by non-primate mammals. In Drug Metabolism — From Microbe to Man, edited by D.V. Parke and R.L. Smith, (London: Taylor and Francis), 299–329.

    Google Scholar 

  17. Gibson G.G. and Skett P. (1986): Introduction to Drug Metabolism, (London: Chapman and Hall).

    Google Scholar 

  18. Chasseaud L.F. and Hawkins D.R. (1990): Biotransformation of drugs. In Encyclopedia of Pharmaceutical Technology, edited by J. Swarbrick and J.C. Boylan, (New York: Marcel Dekker), 129–157.

    Google Scholar 

  19. Fieser L.F. and Fieser M. (1956): Organic Chemistry, (New York: Reinhold Publishing Corporation).

    Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and permissions

About this article

Cite this article

Webber, C., Stokes, C.A., Persiani, S. et al. Absorption, distribution, metabolism and excretion of the cholecystokinin-1 antagonist dexloxiglumide in the dog. European Journal of Drug Metabolism and Pharmacokinetics 29, 15–23 (2004).

Download citation

  • Received:

  • Issue Date:

  • DOI: